Apellis Pharmaceuticals Inc Q3 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : Just a couple from us. I guess just first on commercial and PNH. Just trying to get a sense of kind of the average number of scripts per site. And then maybe like the proportion of REMS site sign-up for the prescribed patients or kind of submitted the new start forms? I know you kind of alluded to the fact that initially physicians might want to start 1 or 2 patients, see how it goes before prescribing more, but curious kind of maybe the breakdown if there have been some sites that have submitted a lot of start forms versus less on some. And then just in terms of geographic atrophy, REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 08, 2021 / 9:30PM, APLS.OQ - Q3 2021 Apellis Pharmaceuticals Inc Earnings Call just curious if you could give us any more color on when we can expect to get the BCVA data or any more info on kind of what happened with the ex U.S. sites in DERBY. I know that some of the ex U.S. work had been ongoing, but just curious kind of how that analysis is going? And I guess, if we can expect to learn more at [AAF].

Question: Matthew W. Luchini - BMO Capital Markets Equity Research - Analyst : Congrats on the quarter. So first on PNH. In the past, you've talked about sort of 12 days average from prescription to first dose. And I was just wondering as the patient population has diversified a little bit, perhaps since last quarter, if there's been any shift in that number or if the inclusion of perhaps a little bit less of your patients, they are taking longer to get through the approval process. And then secondarily, just was curious, there was no mention of it. If there's anything from an inventory perspective that we need to be mindful of this quarter as it relates to the PNH results.

Question: Matthew W. Luchini - BMO Capital Markets Equity Research - Analyst : Yes. Thank you.